KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc.

American Century Companies Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 71.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,072 shares of the specialty pharmaceutical company's stock after selling 24,651 shares during the period. American Century Companies Inc.'s holdings in KalVista Pharmaceuticals were worth $85,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock worth $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in KalVista Pharmaceuticals during the 4th quarter valued at approximately $634,000. Barclays PLC increased its holdings in KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock worth $778,000 after purchasing an additional 54,257 shares during the last quarter. SG Americas Securities LLC increased its holdings in KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter. Finally, FMR LLC raised its position in shares of KalVista Pharmaceuticals by 22.9% in the 3rd quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company's stock valued at $769,000 after purchasing an additional 12,397 shares in the last quarter.

Analysts Set New Price Targets

KALV has been the subject of a number of research analyst reports. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 target price for the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.83.

Remove Ads

KalVista Pharmaceuticals Stock Up 4.0 %

Shares of KALV opened at $11.95 on Tuesday. The firm has a market cap of $594.11 million, a price-to-earnings ratio of -3.28 and a beta of 0.39. The company's fifty day moving average is $11.12 and its 200-day moving average is $10.30. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the transaction, the chief executive officer now owns 287,811 shares of the company's stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was acquired at an average cost of $8.76 per share, with a total value of $382,873.32. Following the transaction, the insider now directly owns 4,986,480 shares of the company's stock, valued at approximately $43,681,564.80. This represents a 0.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. Company insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.